Peter Olson
Impact in
- Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 1%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 20
- Cancer Cells and Metastasis 6
- Pancreatic and Hepatic Oncology Research 6
- Cancer Immunotherapy and Biomarkers 5
-
- Protein Kinase Regulation and GTPase Signaling 11
- Peroxisome Proliferator-Activated Receptors 7
- Melanoma and MAPK Pathways 6
- PI3K/AKT/mTOR signaling in cancer 5
- Metabolism, Diabetes, and Cancer 4
- Co-authors
- Douglas Hanahan (6 shared papers)Ronald Evans (7 shared papers)Morgan Truitt (3 shared papers)Neta Erez (1 shared paper)Chih‐Hao Lee (3 shared papers)Jerrold M. Olefsky (4 shared papers)Andrea Lynn Hevener (3 shared papers)Yaacov Barak (2 shared papers)
- Journals
- Proceedings of the National Academy of Sciences (6 papers)Journal of Medicinal Chemistry (5 papers)Cancer Discovery (4 papers)Clinical Cancer Research (4 papers)Nature Medicine (4 papers)
- Partner nations
- United StatesFranceIsrael
In The Last Decade
Peter Olson
68 papers receiving 10.7k citations
Peter Olson's Hit Papers
Peers
Comparison fields: 5 of 129
- Oncology 4.0k
- Cancer Research 1.8k
- Molecular Biology 5.7k
- Immunology 1.2k
- Physiology 1.2k
Countries citing papers authored by Peter Olson
This map shows the geographic impact of Peter Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Olson more than expected).
Fields of papers citing papers by Peter Olson
This network shows the impact of papers produced by Peter Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Olson. The network helps show where Peter Olson may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Olson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy Hit paper breakdown → | 2011 | 1467 |
| 2 | Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner Hit paper breakdown → | 2010 | 1293 |
| 3 | The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Hit paper breakdown → | 2019 | 1005 |
| 4 | Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle Hit paper breakdown → | 2003 | 844 |
| 5 | 2003 | 763 | |
| 6 | Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor Hit paper breakdown → | 2021 | 550 |
| 7 | Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer Hit paper breakdown → | 2020 | 480 |
| 8 | 2003 | 432 | |
| 9 | 2006 | 423 | |
| 10 | Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer Hit paper breakdown → | 2015 | 421 |
| 11 | Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor Hit paper breakdown → | 2022 | 372 |
| 12 | 2009 | 230 | |
| 13 | 2008 | 170 | |
| 14 | Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer Hit paper breakdown → | 2024 | 152 |
| 15 | MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer Hit paper breakdown → | 2023 | 151 |
| 16 | 2021 | 136 | |
| 17 | 2015 | 132 | |
| 18 | 2017 | 126 | |
| 19 | 2017 | 126 | |
| 20 | 2020 | 120 |
About Peter Olson
Peter Olson is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Epidemiology, having authored 68 papers that have together received 11.0k indexed citations. Recurring topics across this work include Protein Kinase Regulation and GTPase Signaling (11 papers), Peroxisome Proliferator-Activated Receptors (7 papers), Cancer Cells and Metastasis (6 papers), Pancreatic and Hepatic Oncology Research (6 papers), Melanoma and MAPK Pathways (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Metabolism, Diabetes, and Cancer (4 papers). The work is most often cited by research in Oncology (4.0k citations), Cancer Research (1.8k citations), Molecular Biology (5.7k citations), Immunology (1.2k citations) and Physiology (1.2k citations). Peter Olson has collaborated with scholars based in United States, France and Israel. Frequent co-authors include Douglas Hanahan, Ronald Evans, Morgan Truitt, Neta Erez, Chih‐Hao Lee, Jerrold M. Olefsky, Andrea Lynn Hevener, Yaacov Barak, Jamie Le and Margaret A. Tempero. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Medicinal Chemistry, Cancer Discovery, Clinical Cancer Research and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.